A Phase 1/2 interventional study of ODM-201 in Prostate Cancer, sponsored by Orion Corporation, Orion Pharma. Completed at 23 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by Orion Corporation, Orion Pharma · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 23rd largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 1/2, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
Bayer · Sites in China
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
K36 Therapeutics, Inc. · Sites in United States
Ages 18+ · Men only
Region Stockholm · Sites in Sweden
Ages 18+ · Men only
By country, each count listing its studies:
darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 34 · Phase 3 14 · Phase 4 4
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 80 across the 59 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Orion Corporation, Orion Pharma has 6 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies testing darolutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT05762536Erasmus Medical CenterDocetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ODM-201
Drug: ODM-201
Drug: ODM-201
Drug: ODM-201
ODM-201 administered orally daily
Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)
A DLT was any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE version 4.03\]) excluding less than Grade 4 neutropenia or thrombocytopenia, hematological toxicity lasting less than 7 days, and nausea, vomiting, diarrhea controlled with antiemetic and/or anti-diarrheal treatment.
Time frame: Up to 28 days for each cohort
Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose
The MTD is defined as dose level at which 2 or more out of 6 participants experience a dose limiting toxicity (DLT)
Time frame: Up to 28 days for each cohort
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group
Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants who were naïve to both chemotherapy and CYP17 inhibitor
Time frame: 3 months
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group
Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with chemotherapy but not CYP17 inhibitor
Time frame: 3 months
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group
Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with CYP17 inhibitor
Time frame: 3 months
Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naïve and CYP17i-naïve Group
Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.
Time frame: 3 months
Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group
Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.
Time frame: 3 months
Phase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group
Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.
Time frame: 3 months
Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group
Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan
Time frame: 3 months
Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group
Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan
Time frame: 3 months
Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group
Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan
Time frame: 3 months
Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state
AUC(0-8h)
Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state
Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1
Time frame: 1 day
Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state
AUC(0-8h)
Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state
Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1
Time frame: 1 day
Participants were enrolled at 23 hospitals in Europe and in the USA from Apr 5, 2011 to Mar 12, 2013
| Milestone | Phase 1: ODM-201 200 mg/Day | Phase 1: ODM-201 400 mg/Day | Phase 1: ODM-201 600 mg/Day | Phase 1: ODM-201 1000 mg/Day | Phase 1: ODM-201 1400 mg/Day | Phase 1: ODM-201 1800 mg/Day | Phase 2: ODM-201 200mg/Day | Phase 2: ODM-201 400mg/Day | Phase 2: ODM-201 1400mg/Day |
|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 7 | 3 | 4 | 3 | 3 | 38 | 38 | 36 |
| Completed | 3 | 6 | 3 | 3 | 3 | 3 | 35 | 33 | 31 |
| Not completed | 1 | 1 | 0 | 1 | 0 | 0 | 3 | 5 | 5 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
A DLT was any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE version 4.03\]) excluding less than Grade 4 neutropenia or thrombocytopenia, hematological toxicity lasting less than 7 days, and nausea, vomiting, diarrhea controlled with antiemetic and/or anti-diarrheal treatment.
| events | Phase 1: ODM-201 200 mg/Day | Phase 1: ODM-201 400 mg/Day | Phase 1: ODM-201 600 mg/Day | Phase 1: ODM-201 1000 mg/Day | Phase 1: ODM-201 1400 mg/Day | Phase 1: ODM-201 1800 mg/Day |
|---|---|---|---|---|---|---|
| Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 0 |
The MTD is defined as dose level at which 2 or more out of 6 participants experience a dose limiting toxicity (DLT)
| DLTs | Phase 1: ODM-201 200 mg/Day | Phase 1: ODM-201 400 mg/Day | Phase 1: ODM-201 600 mg/Day | Phase 1: ODM-201 1000 mg/Day | Phase 1: ODM-201 1400 mg/Day | Phase 1: ODM-201 1800 mg/Day |
|---|---|---|---|---|---|---|
| Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants who were naïve to both chemotherapy and CYP17 inhibitor
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 600mg/Day ODM-201 | 1000mg/Day ODM-201 | 1400mg/Day ODM-201 | 1800mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group | 6 | 9 | 1 | 1 | 6 | 2 |
Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with chemotherapy but not CYP17 inhibitor
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 600mg/Day ODM-201 | 1000mg/Day ODM-201 | 1400mg/Day ODM-201 | 1800mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group | 5 | 1 | 1 | 1 | 4 | 0 |
Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with CYP17 inhibitor
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 1000mg/Day ODM-201 | 1400mg/Day ODM-201 |
|---|---|---|---|---|
| Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group | 0 | 3 | 0 | 1 |
Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 600mg/Day ODM-201 | 1400mg/Day ODM-201 | 1800mg/Day ODM-201 |
|---|---|---|---|---|---|
| RECIST response CR+PR | 1 | 4 | 0 | 1 | 0 |
| RECIST response CR+PR+SD | 9 | 6 | 2 | 2 | 2 |
Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 1000mg/Day ODM-201 | 1400mg/Day ODM-201 | 1800mg/Day ODM-201 |
|---|---|---|---|---|---|
| RECIST response CR+PR | 1 | 0 | 0 | 1 | 0 |
| RECIST response CR+PR+SD | 5 | 3 | 0 | 4 | 1 |
Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 1400mg/Day ODM-201 |
|---|---|---|---|
| RECIST response CR+PR | 0 | 2 | 0 |
| RECIST response CR+PR+SD | 5 | 9 | 6 |
Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 1000mg/Day ODM-201 | 1400mg/Day ODM-201 | 1800mg/Day ODM-201 |
|---|---|---|---|---|---|
| Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group | 10 | 7 | 1 | 6 | 1 |
Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 600mg/Day ODM-201 | 1000mg/Day ODM-201 | 1400mg/Day ODM-201 |
|---|---|---|---|---|---|
| Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group | 5 | 4 | 1 | 0 | 7 |
Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan
| participants | 200mg/Day ODM-201 | 400mg/Day ODM-201 | 1000mg/Day ODM-201 | 1400mg/Day ODM-201 |
|---|---|---|---|---|
| Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group | 5 | 9 | 1 | 6 |
AUC(0-8h)
| h*ng/mL | 200 mg/Day ODM-201 | 400 mg/Day ODM-201 | 600 mg/Day ODM-201 | 1000 mg/Day ODM-201 | 1400 mg/Day ODM-201 | 1800 mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state | 6387.27 ± 742.01 | 10973.66 ± 5939.78 | 14205.99 ± 2127.26 | 14817.39 ± 4190.48 | 31764.82 ± 8714.06 | 28884.44 ± 4900.60 |
| ng/mL | 200 mg/Day ODM-201 | 400 mg/Day ODM-201 | 600 mg/Day ODM-201 | 1000 mg/Day ODM-201 | 1400 mg/Day ODM-201 | 1800 mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state | 1011.67 ± 168.84 | 1757.57 ± 858.72 | 2033.00 ± 277.59 | 2392.33 ± 406.63 | 4459.00 ± 1163.10 | 4235.00 ± 617.80 |
| h | 200 mg/Day ODM-201 | 400 mg/Day ODM-201 | 600 mg/Day ODM-201 | 1000 mg/Day ODM-201 | 1400 mg/Day ODM-201 | 1800 mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1 | 3.00 ± 1.63 | 3.00 ± 0.73 | 3.00 ± 0.92 | 5.08 ± 1.47 | 3.00 ± 1.15 | 5.00 ± 1.51 |
AUC(0-8h)
| h*ng/mL | 200 mg/Day ODM-201 | 400 mg/Day ODM-201 | 600 mg/Day ODM-201 | 1000 mg/Day ODM-201 | 1400 mg/Day ODM-201 | 1800 mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state | 11754.23 ± 5161.80 | 15501.56 ± 2755.85 | 24902.56 ± 12129.79 | 29980.83 ± 11658.75 | 63531.81 ± 15798.30 | 64435.97 ± 22930.30 |
| ng/mL | 200 mg/Day ODM-201 | 400 mg/Day ODM-201 | 600 mg/Day ODM-201 | 1000 mg/Day ODM-201 | 1400 mg/Day ODM-201 | 1800 mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state | 1850.00 ± 654.83 | 2491.43 ± 328.86 | 3963.33 ± 1935.21 | 4643.33 ± 1340.01 | 9336.67 ± 2054.27 | 9406.67 ± 3165.38 |
| h | 200 mg/Day ODM-201 | 400 mg/Day ODM-201 | 600 mg/Day ODM-201 | 1000 mg/Day ODM-201 | 1400 mg/Day ODM-201 | 1800 mg/Day ODM-201 |
|---|---|---|---|---|---|---|
| Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1 | 3.00 ± 1.63 | 1.52 ± 1.33 | 3.00 ± 0.92 | 5.04 ± 2.05 | 3.00 ± 1.15 | 5.00 ± 0.55 |
Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1, 200mg/Day ODM-201 | — | 0/4 (0%) | 4/4 (100%) |
| Phase 1, 400mg/Day ODM-201 | — | 2/7 (28.6%) | 5/7 (71.4%) |
| Phase 1, 600mg/Day ODM-201 | — | 0/3 (0%) | 2/3 (66.7%) |
| Phase 1, 1000mg/Day ODM-201 | — | 1/4 (25%) | 4/4 (100%) |
| Phase 1, 1400mg/Day ODM-201 | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1, 1800mg/Day ODM-201 | — | 0/3 (0%) | 2/3 (66.7%) |
| Phase 2, 200mg/Day ODM-201 | — | 2/38 (5.3%) | 33/38 (86.8%) |
| Phase 2, 400mg/Day ODM-201 | — | 3/37 (8.1%) | 35/37 (94.6%) |
| Phase 2, 1400mg/Day ODM-201 | — | 4/35 (11.4%) | 27/35 (77.1%) |
| Event | Phase 1, 200mg/Day ODM-201 | Phase 1, 400mg/Day ODM-201 | Phase 1, 600mg/Day ODM-201 | Phase 1, 1000mg/Day ODM-201 | Phase 1, 1400mg/Day ODM-201 | Phase 1, 1800mg/Day ODM-201 | Phase 2, 200mg/Day ODM-201 | Phase 2, 400mg/Day ODM-201 | Phase 2, 1400mg/Day ODM-201 |
|---|---|---|---|---|---|---|---|---|---|
| Urinary retentionRenal and urinary disorders | 0/4 | 0/7 | 0/3 | 0/4 | 1/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| Hand fractureInjury, poisoning and procedural complications | 0/4 | 0/7 | 0/3 | 1/4 | 0/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| LacerationInjury, poisoning and procedural complications | 0/4 | 0/7 | 0/3 | 1/4 | 0/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| Muscle injuryInjury, poisoning and procedural complications | 0/4 | 0/7 | 0/3 | 1/4 | 0/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| General physical health deteriorationGeneral disorders | 0/4 | 1/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| Staphylococcal infectionInfections and infestations | 0/4 | 1/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| Cerebral ischaemiaNervous system disorders | 0/4 | 1/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| PneumoniaInfections and infestations | 0/4 | 0/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 0/37 | 1/35 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 0/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 1/37 | 1/35 |
| Bone painMusculoskeletal and connective tissue disorders | 0/4 | 0/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 0/37 | 1/35 |
| Event | Phase 1, 200mg/Day ODM-201 | Phase 1, 400mg/Day ODM-201 | Phase 1, 600mg/Day ODM-201 | Phase 1, 1000mg/Day ODM-201 | Phase 1, 1400mg/Day ODM-201 | Phase 1, 1800mg/Day ODM-201 | Phase 2, 200mg/Day ODM-201 | Phase 2, 400mg/Day ODM-201 | Phase 2, 1400mg/Day ODM-201 |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/4 | 1/7 | 1/3 | 0/4 | 0/3 | 2/3 | 0/38 | 4/37 | 1/35 |
| GynaecomastiaReproductive system and breast disorders | 0/4 | 0/7 | 0/3 | 0/4 | 2/3 | 0/3 | 1/38 | 1/37 | 0/35 |
| Oedema peripheralGeneral disorders | 2/4 | 0/7 | 0/3 | 0/4 | 1/3 | 0/3 | 2/38 | 0/37 | 4/35 |
| StomatitisGastrointestinal disorders | 2/4 | 0/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 0/37 | 0/35 |
| AstheniaGeneral disorders | 2/4 | 2/7 | 0/3 | 0/4 | 0/3 | 0/3 | 0/38 | 1/37 | 0/35 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/4 | 0/7 | 0/3 | 0/4 | 0/3 | 0/3 | 1/38 | 0/37 | 0/35 |
| ConstipationGastrointestinal disorders | 1/4 | 1/7 | 0/3 | 0/4 | 0/3 | 1/3 | 5/38 | 6/37 | 2/35 |
| NauseaGastrointestinal disorders | 1/4 | 0/7 | 0/3 | 1/4 | 0/3 | 1/3 | 4/38 | 4/37 | 3/35 |
| FatigueGeneral disorders | 0/4 | 0/7 | 0/3 | 1/4 | 1/3 | 1/3 | 7/38 | 8/37 | 5/35 |
| Hot flushVascular disorders | 0/4 | 0/7 | 0/3 | 0/4 | 0/3 | 1/3 | 2/38 | 4/37 | 2/35 |
Safety
| Age, Continuous(years) | Phase 1, 200mg/Day ODM-201 | Phase 1, 400mg/Day ODM-201 | Phase 1, 600mg/Day ODM-201 | Phase 1, 1000mg/Day ODM-201 | Phase 1, 1400mg/Day ODM-201 | Phase 1, 1800mg/Day ODM-201 | Phase 2 (200mg/Day ODM-201) | Phase 2 (400mg/Day ODM-201) | Phase 2 (1400mg/Day ODM-201) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 73 ± 1.4 | 71.9 ± 8.5 | 65.3 ± 3.5 | 65.8 ± 11.2 | 67.7 ± 5.5 | 67.7 ± 3.2 | 68.3 ± 7.0 | 69.1 ± 7.4 | 71.3 ± 8.0 | 69.4 ± 7.4 |
| Sex: Female, Male(Participants) | Phase 1, 200mg/Day ODM-201 | Phase 1, 400mg/Day ODM-201 | Phase 1, 600mg/Day ODM-201 | Phase 1, 1000mg/Day ODM-201 | Phase 1, 1400mg/Day ODM-201 | Phase 1, 1800mg/Day ODM-201 | Phase 2 (200mg/Day ODM-201) | Phase 2 (400mg/Day ODM-201) | Phase 2 (1400mg/Day ODM-201) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 4 | 7 | 3 | 4 | 3 | 3 | 38 | 37 | 35 | 134 |
The record gives a start of Mar 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darolutamide
Orion Corporation, Orion Pharma →